Andrew Stewart Plump Sells 19,651 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Andrew Stewart Plump sold 19,651 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $18.49, for a total transaction of $363,346.99. Following the completion of the sale, the insider directly owned 261,656 shares in the company, valued at approximately $4,838,019.44. The trade was a 6.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Stewart Plump also recently made the following trade(s):

• On Monday, August 10th, Andrew Stewart Plump sold 165,393 shares of Takeda Pharmaceutical stock. The shares were sold at an average price of $17.10, for a total transaction of $2,828,220.30.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock traded up $0.04 during midday trading on Friday, reaching $18.17. 1,479,067 shares of the stock were exchanged, compared to its average volume of 3,162,046. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.90. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The firm has a market cap of $58.22 billion, a PE ratio of 53.44 and a beta of -0.08. The company’s fifty day moving average is $16.75 and its 200-day moving average is $17.18.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.17 by $0.30. The firm had revenue of $7.50 billion during the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. On average, sell-side analysts forecast that Takeda Pharmaceutical Co. will post 1.54 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on TAK. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Finally, Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold”.

Institutional Trading of Takeda Pharmaceutical

A number of hedge funds have recently made changes to their positions in TAK. Royal Bank of Canada raised its position in Takeda Pharmaceutical by 11.0% during the first quarter. Royal Bank of Canada now owns 441,054 shares of the company’s stock valued at $6,558,000 after purchasing an additional 43,706 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Takeda Pharmaceutical by 43.6% during the 1st quarter. AQR Capital Management LLC now owns 195,740 shares of the company’s stock valued at $2,911,000 after purchasing an additional 59,442 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Takeda Pharmaceutical by 15.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after purchasing an additional 692,404 shares during the last quarter. Focus Partners Wealth raised its holdings in shares of Takeda Pharmaceutical by 4.1% during the 1st quarter. Focus Partners Wealth now owns 82,738 shares of the company’s stock valued at $1,230,000 after buying an additional 3,239 shares in the last quarter. Finally, Sivia Capital Partners LLC purchased a new position in shares of Takeda Pharmaceutical during the 2nd quarter valued at about $351,000. 9.17% of the stock is owned by institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.